Description

Soritmik (sotalol hydrochloride) tablets 0.16 g. №20

Ingredients

Active ingredient: Sotalol hydrochloride 0.16 g per tablet.

Dosage

Dosage: The usual dose is 80 mg twice daily. Dosage may vary depending on the condition being treated. Always follow your healthcare provider’s instructions.

Indications

Indications: Soritmik tablets are indicated for the treatment of documented ventricular arrhythmias and certain types of atrial arrhythmias.

Contraindications

Contraindications: Do not use Soritmik if you have a history of bronchial asthma, certain heart conditions, severe kidney impairment, or electrolyte imbalances.

Directions

Directions: Take Soritmik exactly as prescribed by your doctor. Swallow the tablet whole with a full glass of water. Do not crush or chew the tablet.

Scientific Evidence

Sotalol hydrochloride, the active ingredient in Soritmik, is a non-selective beta-blocker with Class III antiarrhythmic properties. It prolongs the action potential duration and refractory period in cardiac tissues, leading to its antiarrhythmic effects. Studies have shown that sotalol is effective in reducing the recurrence of ventricular arrhythmias and maintaining sinus rhythm in atrial fibrillation.

Additional Information

It is important to regularly monitor your heart rhythm and blood pressure while taking Soritmik. Avoid sudden discontinuation of the medication, as it may lead to worsening of arrhythmias. Inform your healthcare provider about all medications you are taking to avoid potential drug interactions.

Pharmacological Effects: Sotalol hydrochloride exerts its pharmacological action by blocking beta-adrenergic receptors in the heart, leading to a decrease in heart rate and contractility. Additionally, its Class III antiarrhythmic properties help in the management of various types of arrhythmias.

Clinical Trials: Clinical trials have demonstrated the efficacy of sotalol in reducing the frequency of ventricular arrhythmias and improving the quality of life in patients with arrhythmias. Comparative studies have shown sotalol to be as effective as other antiarrhythmic agents with a favorable safety profile.